Keymed Biosciences Inc.

Keymed Biosciences Inc., a biotechnology company provides the discovery and development of biological therapies in the autoimmune and oncology therapeutic areas in Mainland China, the United States, and the United Kingdom. The company develops Kangyueda for the treatment of moderate-to-severe atopic dermatitis in adults, chronic rhinosinusitis with nasal polyps, and seasonal allergic rhinitis.

Its portfolio also includes CMG901/AZD0901, an antibody drug conjugate for treatment of advanced solid tumors, CM512, a TSLP x IL-13 bispecific antibody in Phase I clinical study, and CM518D1, an antibody drug conjugate drug in open-label Phase I/II clinical trial.

It is also developing CM336, a CMA x CD3 bispecific antibody in an open-label Phase I/II clinical study for the treatment of patients with relapsed or refractory multiple myeloma.

Its portfolio also includes CM313 in Phase II clinical study in subjects with primary immune thrombocytopenia, CM383, an Aß protofibrils antibody in Phase Ib clinical study, and CM559, a N3pG Aß antibody in Phase I clinical study.

Additionally, it is involved in the development of CM350, a GPC3 x CD3 bispecific antibody in Phase I/II clinical study. Its portfolio also includes CM326, a TSLP antibody, CM355/ICP-B02/PRO-203, a CD20 x CD3 bispecific antibody, and CM369/ICP-B05, an anti-C-C motif chemokine receptor 8 monoclonal antibody.

It has an out-licence agreement with Belenos Biosciences, Inc. Its portfolio also includes Platina Medicines Ltd, Prolium Biosciences, Inc., and Timberlyne Therapeutics, Inc. Founded in 2016, The company was formerly known as 2Health Biosciences, Inc. Keymed Biosciences is headquartered in Chengdu, the People's Republic of China.